Martin Johnson
Overview
Explore the profile of Martin Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
2141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson M, Lin Y, Schmidt H, Sunnaker M, van Maanen E, Huang X, et al.
Br J Clin Pharmacol
. 2024 Aug;
90(12):3263-3276.
PMID: 39160062
Aims: Osimertinib is a third-generation, irreversible, central nervous system-active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with efficacy in EGFR-mutated non-small cell lung cancer (NSCLC). We assessed the...
2.
Sustainably cultured coral scaffold supports human bone marrow mesenchymal stromal cell osteogenesis
Gentili C, Palama M, Sexton G, Maybury S, Shanahan M, Omowunmi-Kayode Y, et al.
Regen Ther
. 2024 Jul;
26:366-381.
PMID: 39050552
The current gold standard grafting material is autologous bone due to its osteoinductive and osteoconductive properties. Autograft harvesting results in donors site morbidity. Coral scaffolds offer a natural autograft alternative,...
3.
Johnson M, Kaschek D, Ghiorghiu D, Lanke S, Miah K, Schmidt H, et al.
J Clin Pharmacol
. 2024 Jul;
64(11):1419-1431.
PMID: 39031510
Adavosertib (AZD1775) is a potent small-molecule inhibitor of Wee1 kinase. This analysis utilized pharmacokinetic data from 8 Phase I/II studies of adavosertib to characterize the population pharmacokinetics of adavosertib in...
4.
Wanika L, Evans N, Johnson M, Tomkinson H, Chappell M
Clin Transl Sci
. 2024 Mar;
17(3):e13714.
PMID: 38477045
Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the...
5.
Pepke-Zaba J, Howard L, Kiely D, Sweeney S, Johnson M
Adv Respir Med
. 2024 Jan;
92(1):45-57.
PMID: 38247551
Chronic thromboembolic pulmonary disease (CTEPD) is a complication of pulmonary embolism (PE). We conducted an online survey of UK PE-treating physicians to understand practices in the follow-up of PE and...
6.
Stubbs H, Lua S, Ingram J, Jani B, Brewis M, Church C, et al.
Pulm Circ
. 2023 Dec;
13(4):e12325.
PMID: 38148951
Remote exercise tests for patients with pulmonary hypertension (PH) would improve the telemedicine strategies in this disease. The PHRET study assessed the validity and feasibility of four remote exercise tests...
7.
Maayeh M, Cavus O, Hassen L, Johnson M, Summerfield T, Begom M, et al.
Am Heart J
. 2023 Dec;
269:45-55.
PMID: 38103586
Background: Pre-eclampsia with severe features (severe PreE) is associated with heart dysfunction, yet the impact beyond pregnancy, including its association with cardiomyopathic genetic polymorphisms, remains poorly understood. Objective: We aimed...
8.
Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(2):349-360.
PMID: 38010260
This exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics and predict disease progression in patients with treatment-naïve locally advanced/metastatic epidermal growth factor receptor mutation (EGFRm)-positive non-small...
9.
Karia N, Howard L, Johnson M, Kiely D, Lordan J, McCabe C, et al.
Eur Heart J
. 2023 Aug;
44(44):4678-4691.
PMID: 37619574
Background And Aims: Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg)...
10.
Arogundade F, Jani B, Church C, Brewis M, Johnson M, Stubbs H
Pulm Circ
. 2023 Jul;
13(3):e12257.
PMID: 37404903
Risk stratification models in pulmonary arterial hypertension (PAH) rely on World Health Organisation Functional Class (WHO FC). A high proportion of patients are classified as WHO FC III, a heterogenous...